insulin detemir
Selected indexed studies
- Insulin degludec versus insulin detemir, both in combination with insulin aspart, in the treatment of pregnant women with type 1 diabetes (EXPECT): an open‑label, multinational, randomised, controlled, non-inferiority trial. (Lancet Diabetes Endocrinol, 2023) [PMID:36623517]
- Insulin detemir. Novo Nordisk. (Curr Opin Investig Drugs, 2003) [PMID:12808886]
- Pharmacology of insulin detemir. (Endocrinol Metab Clin North Am, 2007) [PMID:17881328]
_Worker-drafted node — pending editorial review._
Connections
insulin detemir is a side effect of
Sources
- Safety and efficacy of insulin detemir vs. insulin NPH in pregnant women with diabetes: a systematic review and meta-analysis. (2024) pubmed
- Insulin degludec versus insulin detemir, both in combination with insulin aspart, in the treatment of pregnant women with type 1 diabetes (EXPECT): an open‑label, multinational, randomised, controlled, non-inferiority trial. (2023) pubmed
- Insulin detemir. Novo Nordisk. (2003) pubmed
- Pharmacology of insulin detemir. (2007) pubmed
- Insulin detemir in the treatment of type 1 and type 2 diabetes. (2006) pubmed
- [Insulin detemir(NN-304)]. (2001) pubmed
- Insulin detemir: a review. (2006) pubmed
- Basal insulin: physiology, pharmacology, and clinical implications. (2011) pubmed
- Insulin detemir--a new basal insulin analog. (2005) pubmed
- Insulin detemir: a review of its use in the management of diabetes mellitus. (2012) pubmed